AES-350 |
| رقم الكتالوجGC48775 |
AES-350 هو مثبط HDAC6 قوي وفعال عن طريق الفم مع IC50 و Ki من 0.0244 ميكرومتر و 0.035 ميكرومتر ، على التواليAES-350 هو أيضًا ضد HDAC3 و HDAC8 في اختبار النشاط الأنزيمي بقيم IC50 0.187 ميكرومتر و 0.245 ميكرومتر ، على التوالييؤدي AES-350 إلى موت الخلايا المبرمج في خلايا AML من خلال تثبيط HDAC ويمكن استخدامه لأبحاث سرطان الدم النخاعي الحاد (AML)
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 847249-57-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
AES-350 is an inhibitor of class I histone deacetylases (HDACs; IC50s = 0.605, 0.187, and 0.245 µM for HDAC1, -3, and -8, respectively) and class IIb HDACs (IC50s = 0.0244 and 0.899 µM for HDAC6 and HDAC10, respectively).1 It is selective for class I and class IIb HDACs over HDAC2, -4, -5, -7, -9, and -11 (IC50s = >1 µM for all). AES-350 is cytotoxic to MV4-11, MOLM-13, and MRC-9 cells (IC50s = 0.576, 6, and 33.2 µM, respectively). It induces apoptosis in MV4-11 cells in a concentration-dependent manner.
1.Shouksmith, A.E., Gawel, J.M., Nawar, N., et al.Class I/IIb-selective HDAC inhibitor exhibits oral bioavailability and therapeutic efficacy in acute myeloid leukemiaACS Med. Chem. Lett.11(1)56-64(2019)
Average Rating: 5 (Based on Reviews and 22 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *